Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PM
PharmaCyte Biotech, Inc. Common Stock
PMCB
Mkt Cap
$3.7M
Volume
32.94K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PM
PMCB
PM
PharmaCyte Biotech, Inc. Common Stock
PMCB
News
·
Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider
Mkt Cap
$3.8M
Volume
32.94K
Next Earnings
N/A
Chart
Financials
Earnings
News
About
Insider
Filings
Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider
The pancreatic cancer treatment market is expected to grow significantly, driven by the increasing prevalence of the disease and the development of innovative therapies. Factors like the rising geriatric population, emerging chemotherapies, and increased healthcare investments in Asia-Pacific and the Middle East are further propelling the market growth.
GlobeNewswire Inc. · Aug 27, 2024
Meta Platforms Announces $40 Billion Share Buyback - Buyback Wednesdays
Meta Platforms, Inc. announced a whopping $40 billion share repurchase program.
Seeking Alpha · Feb 9, 2023
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®
GlobeNewswire Inc. · Oct 7, 2022
Wall Street Breakfast: What Moved Markets
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Seeking Alpha · Aug 14, 2021
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Aug. 6) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Candel Therapeutics, Inc. (NASDAQ: CADL) (IPOed July 26) Century Therapeutics, Inc. (NASDAQ: IPSC) (reacted to its second-quarter results) Dynavax Technologies Corporation (NASDAQ: DVAX) Gilead Sciences, Inc. (NASDAQ: GILD) Harvard Bioscience, Inc. (NASDAQ: HBIO) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Innoviva, Inc. (NASDAQ: INVA) Johnson & Johnson (NYSE: JNJ) Sesen Bio, Inc. (NASDAQ: SESN) Tenaya Therapeutics, Inc. (NASDAQ: TNYA) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 12) ABVC BioPharma, Inc. (NASDAQ: ABVC) (announced its second-quarter results) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Achilles Therapeutics plc (NASDAQ: ACHL) Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) Akero Therapeutics, Inc. (NASDAQ: AKRO) Allogene Therapeutics, Inc. (NASDAQ: ALLO) Alzamend Neuro, Inc. (NASDAQ: ALZN) Aprea Therapeutics, Inc. (NASDAQ: APRE) (announced that FDA imposed clinical hold on lymphoid malignancy study) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) (announced second-quarter results) Atai Life Sciences N.V. (NASDAQ: ATAI) (announced setting up of a subsidiary for studying Salvinorin A for mental health disorders) Axsome Therapeutics, Inc. (NASDAQ: AXSM) Aytu Biopharma, Inc. (NASDAQ: AYTU) Baudax Bio, Inc. (NASDAQ: BXRX) Baxter International Inc. (NYSE: BAX) Biodesix, Inc. (NASDAQ: BDSX) Biomea Fusion, Inc. (NASDAQ: BMEA) Cellectar Biosciences, Inc. (NASDAQ: CLRB) Celularity Inc. (NASDAQ: CELU) Codex DNA, Inc. (NASDAQ: DNAY) CytomX Therapeutics, Inc. (NASDAQ: CTMX) DiaMedica Therapeutics Inc. (NASDAQ: DMAC) (reacted to its second-quarter results) Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) Edgewise Therapeutics, Inc. (NASDAQ: EWTX) Ensysce Biosciences, Inc. (NASDAQ: ENSC) Epizyme, Inc. (NASDAQ: EPZM) Exicure, Inc. (NASDAQ: XCUR) (announced its second-quarter results) EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) FibroGen, Inc. (NASDAQ: FGEN) Flexion Therapeutics, Inc. (NASDAQ: FLXN) Grifols, S.A. (NASDAQ: GRFS) Heron Therapeutics, Inc. (NASDAQ: HRTX) HOOKIPA Pharma Inc. (NASDAQ: HOOK) (reacted to its second-quarter result) Hoth Therapeutics, Inc. (NASDAQ: HOTH) IMARA Inc. (NASDAQ: IMRA) IN8bio, Inc. (NASDAQ: INAB) Incyte Corporation (NASDAQ: INCY) Inhibikase Therapeutics, Inc. (NASDAQ: IKT) iRhythm Technologies, Inc. (NASDAQ: IRTC) Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Kronos Bio, Inc. (NASDAQ: KRON) Lava Therapeutics B.V. (NASDAQ: LVTX) Liminal BioSciences Inc. (NASDAQ: LMNL) Lumos Pharma, Inc. (NASDAQ: LUMO) MediciNova, Inc. (NASDAQ: MNOV) Moleculin Biotech, Inc. (NASDAQ: MBRX) (reacted to its second-quarter ...
Benzinga · Aug 13, 2021
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Cytek Biosciences, Inc. (NASDAQ: CTKB) Dynavax Technologies Corporation (NASDAQ: DVAX) Eliem Therapeutics, Inc. (NASDAQ: ELYM) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Adicet Bio, Inc. (NASDAQ: ACET) Akero Therapeutics, Inc. (NASDAQ: AKRO) Allogene Therapeutics, Inc. (NASDAQ: ALLO) Aptose Biosciences Inc. (NASDAQ: APTO) Ardelyx, Inc. (NASDAQ: ARDX) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) AVROBIO, Inc. (NASDAQ: AVRO) Baudax Bio, Inc. (NASDAQ: BXRX) Biodesix, Inc. (NASDAQ: BDSX) (reacted to second-quarter results) Cellectar Biosciences, Inc. (NASDAQ: CLRB) Celularity Inc. (NASDAQ: CELU) Codex DNA, Inc. (NASDAQ: DNAY) (announced second-quarter results) CytomX Therapeutics, Inc. (NASDAQ: CTMX) Edgewise Therapeutics, Inc. (NASDAQ: EWTX) Ensysce Biosciences, Inc. (NASDAQ: ENSC) Epizyme, Inc. (NASDAQ: EPZM) Eton Pharmaceuticals, Inc. (NASDAQ: ETON) Exicure, Inc. (NASDAQ: XCUR) EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) FibroGen, Inc. (NASDAQ: FGEN) (received a complete response letter for its anemia drug regulatory application) Freeline Therapeutics Holdings plc (NASDAQ: FRLN) Grifols, S.A. (NASDAQ: GRFS) Harpoon Therapeutics, Inc. (NASDAQ: HARP) Ikena Oncology, Inc. (NASDAQ: IKNA) IMARA Inc. (NASDAQ: IMRA) Incyte Corporation (NASDAQ: INCY) Inventiva S.A. (NASDAQ: IVA) iRhythm Technologies, Inc. (NASDAQ: IRTC) Kamada Ltd. (NASDAQ: KMDA) (announced second-quarter results) Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Kronos Bio, Inc. (NASDAQ: KRON) Kura Oncology, Inc. (NASDAQ: KURA) Lumos Pharma, Inc. (NASDAQ: LUMO) Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) MediciNova, Inc. (NASDAQ: MNOV) Nautilus Biotechnology, Inc. (NASDAQ: NAUT) Nektar Therapeutics (NASDAQ: NKTR) Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Nevro Corp. (NYSE: NVRO) Nuvation Bio Inc. (NYSE: NUVB) OptiNose, Inc. (NASDAQ: OPTN) Otonomy, Inc. (NASDAQ: OTIC) Outset Medical, Inc. (NASDAQ: OM) PharmaCyte Biotech, Inc. Common Stock (NASDAQ: PMCB) Relmada Therapeutics, Inc. (NASDAQ: RLMD) (announced second-quarter results) Rockwell ...
Benzinga · Aug 12, 2021
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PM
PMCB
PharmaCyte Biotech, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PMCB
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PMCB yet.
Related Tickers
Earnings